Clean Science and Technology Limited — Investor Meet, 26-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Clean Science reported its highest-ever sales volumes in FY ’25, with consolidated Q4 revenue up 14% YoY to Rs. 256 Cr and EBITDA margin stable at 41%. HALS segment sales reached Rs. 80 Cr (1,900 tons), targeting 4,500 tons and Rs. 210 Cr in FY ’26, aiming full capacity by FY ’28. Exports to Europe, US, and Middle East are growing alongside ~50% domestic market penetration, with scope to reach 65%. New performance chemicals projects remain on track for H2 FY ’26 commercialization with Rs. 300 Cr CAPEX. Management expects ~40% consolidated EBITDA margin in FY ’26, driven by pharma and performance segments, while working capital rise linked to HALS scale-up should normalize post-ramp-up. R&D spend was Rs. 5.5 Cr focused on quality innovation. Confident growth outlook backed by new launches and a $1.5 billion expanding market.